FDA & Government News

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

Share

  • 1

    Dupilumab approved for AFRS patients aged 6 and older.

  • 2

    First FDA-specific treatment for allergic fungal rhinosinusitis.

  • 3

    Significant reduction in sinus opacification observed.

  • 4

    Improved nasal polyp size and nasal congestion.

  • 5

    Less need for systemic corticosteroids and surgeries.

  • 6

    Safety profile aligns with previous data.

  • 7

    Most common side effects include injection-site reactions and eosinophilia.

  • 8

    Pediatric data based on adult trials.

Original Source(s)

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

  • by Kathryn Wighton

  • February 25, 2026

  • 2 min

Related Content

Connecting the Diagnostic Dots in HIES

Clinical case report highlights how classic features of STAT3 hyper-IgE syndrome can be routinely missed in pediatric practice

Staffing, Flexibility Top Nurses' List to Return

Two-thirds of former hospital nurses would consider coming back if workplace conditions improved, survey finds

Vaccine Playbook Rewrite: Who’s In Charge?

HHS Secretary Robert F. Kennedy Jr.’s changes at the CDC are prompting states and medical societies to issue independent vaccine recommendations, challenging long-standing national immunization policy.